Evolving molecular therapy for chronic myeloid leukaemia--are we on target? (Q36276288)

13 August 2017

1 reference

title

Evolving molecular therapy for chronic myeloid leukaemia--are we on target? (English)

1 reference

13 August 2017

1 reference

Mhairi Copland

1

0 references

Heather G Jørgensen

object named as

Heather G Jørgensen

series ordinal

2

0 references

Tessa Holyoake

object named as

Tessa L Holyoake

series ordinal

3

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

10

1 reference

13 August 2017

5

1 reference

13 August 2017

349-359

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Clinical significance of long-term cultures of myeloid blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib alone and in combination for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330500234195

10.1080/10245330500234195

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16203604